Skip to main content
SpringerLink
Log in

Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer

  • Living reference work entry
  • First Online:
Urologic Oncology

  • 135 Accesses

Abstract

The development of clinically or pathologically involved regional lymph nodes represents the most clinically impactful event in patients with penile squamous cell carcinoma (PSCC), and prognosis is dismal despite adequate treatment. Surgery, the mainstay of treatment, is insufficient as a stand-alone option in most cases, and multimodal approaches are recommended for these patients.

Additionally, huge uncertainties still characterize two important details of surgical extent: the need for pelvic extent and the role of contralateral lymphadenectomy.

Despite chemotherapy activity is frustratingly poor in PSCC, there are evidence in the literature supporting its use in the neoadjuvant or adjuvant setting in patients with extensite lymph node involvement. Conversely, very limited data are available regarding the use of perioperative radiotherapy on the inguinal lymph nodes. Therefore, clinical trials and multidisciplinary collaboration are needed in PSCC, along with multicenter collaborations aimed at identifying the optimal therapeutic pathways in this rare and complex tumor.

Conflict of Interest Statement

None of the authors have a relevant conflict of interest to disclose.

Funding

This work was not supported by any grant funding.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ali SM, Pal SK, Wang K, et al. Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations. Oncologist. 2016;21:33–9.

    Article  CAS  Google Scholar 

  • Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014;113:871–7.

    Article  CAS  Google Scholar 

  • Corral DA, Sella A, Pettaway CA, et al. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998;160:1770–4.

    Article  CAS  Google Scholar 

  • Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol. 2003;170:359–65.

    Article  Google Scholar 

  • Dexeus FH, Logothetis CJ, Sella A, et al. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991;146:1284–7.

    Article  CAS  Google Scholar 

  • Dickstein RJ, Munsell MF, Pagliaro LC, et al. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int. 2016;117:118–25.

    Article  CAS  Google Scholar 

  • Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer. 2015;13:44–9.

    Article  Google Scholar 

  • Franks KN, Kancherla K, Sethugavalar B, et al. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol. 2011;186:524–9.

    Article  Google Scholar 

  • Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999;161:1823–5.

    Article  CAS  Google Scholar 

  • Hakenberg OW, Nippgen JB, Froehner M, et al. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006;98:1225–7.

    Article  CAS  Google Scholar 

  • Hakenberg OW, Comperat EM, Minhas S, et al. EAU guidelines on penile cancer: 2014 update. Eur Urol. 2015;67:142–50.

    Article  Google Scholar 

  • Horenblas S. Lymphadenectomy in penile cancer. Urol Clin N Am. 2011;38:459–69.

    Article  Google Scholar 

  • McDaniel AS, Hovelson DH, Cani AK, et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Cancer Res. 2015;75:5219–27.

    Article  CAS  Google Scholar 

  • Nadal R, Mortazavi A, Stein M, et al. 846O – Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. 2017 annual meeting of the European Society for Medical Oncology, Madrid, 8–12 Sept 2017.

    Google Scholar 

  • National Comprehensive Cancer Network. NCCN guidelines: penile cancer. 2018. https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf

  • Necchi A. Systemic therapy for penile cancer. Eur Urol Suppl. 2017. https://doi.org/10.1016/j.eursup.2017.07.003.

    Article  Google Scholar 

  • Necchi A, Nicolai N, Colecchia M, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011;29:e650–2.

    Article  Google Scholar 

  • Necchi A, Lo Vullo S, Nicolai N, et al. Prognostic factors of adjuvant taxane, cisplatin, and 5-fluorouracil chemotherapy for patients with penile squamous cell carcinoma after regional lymphadenectomy. Clin Genitourin Cancer. 2016a;14:518–23.

    Article  Google Scholar 

  • Necchi A, Eigl BJ, Yang ES, et al. Gene expression profiling of advanced penile squamous cell carcinoma receiving cisplatin-based chemotherapy improves prognostication and identifies potential therapeutic targets. Eur Urol Focus. 2016b. https://doi.org/10.1016/j.euf.2016.08.001 (Epub ahead of print).

  • Necchi A, Giannatempo P, Lo Vullo S, et al. Panitumumab treatment for advanced penile squamous cell carcinoma when surgery and chemotherapy have failed. Clin Genitourin Cancer. 2016c;14:231–6.

    Article  Google Scholar 

  • Necchi A, Pond GR, Raggi D, et al. Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous cell carcinoma: results of a multicentre analysis. Clin Genitourin Cancer. 2017a. https://doi.org/10.1016/j.clgc.2017.02.002 (Epub ahead of print).

    PubMed  Google Scholar 

  • Necchi A, Lo Vullo S, Perrone F, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: results of an open label, single-arm, single-center, phase 2 study. BJU Int. 2017b. https://doi.org/10.1111/bju.14013 (in press).

    Article  Google Scholar 

  • Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer. 2013;109:2554–9.

    Article  CAS  Google Scholar 

  • Nicolai N, Sangalli LM, Necchi A, et al. A combination of cisplatin and 5-fluorouracil with a taxane in patients who underwent lymph node dissection for nodal metastases from squamous cell carcinoma of the penis: treatment outcome and survival analyses in neoadjuvant and adjuvant settings. Clin Genitourin Cancer. 2016;14:323–30.

    Article  Google Scholar 

  • Ottenhof S, et al. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J Urol. 2017 Mar;197(3 Pt 1):690–7.

    Article  Google Scholar 

  • Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28:3851–7.

    Article  CAS  Google Scholar 

  • Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27:823–4.

    Article  CAS  Google Scholar 

  • Pond GR, Milowsky MI, Kolinsky MP, et al. Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. Clin Genitourin Cancer. 2014;12:440–6.

    Article  Google Scholar 

  • Sharma P, Djajadiningrat R, Zargar-Shoshtari K, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol. 2015;33:496.e17–23.

    Article  Google Scholar 

  • Sonpavde G, Pagliaro LC, Buonerba C, et al. Penile cancer: current therapy and future directions. Ann Oncol. 2013;24:1179–89.

    Article  CAS  Google Scholar 

  • Theodore C, Skoneczna I, Bodrogi I, et al. A phase II multicentre study of irinotecan (CPT11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008;19:1304–7.

    Article  CAS  Google Scholar 

  • Trabulsi EJ, Hoffman-Censits J. Chemotherapy for penile and urethral carcinoma. Urol Clin N Am. 2010;37:467–74.

    Article  Google Scholar 

  • Udager AM, Liu TY, Skala SL, et al. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol. 2016;27:1706–12.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

    Andrea Necchi, Daniele Raggi & Patrizia Giannatempo

Authors
  1. Andrea Necchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Raggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrizia Giannatempo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Necchi .

Editor information

Editors and Affiliations

  1. Urologie, Univ Lübeck, Lübeck, Schleswig-Holstein, Germany

    Axel Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Universitätsklinikum Rostock , Urologische Klinik und Poliklinik, Rostock, Germany

    Chris Protzel

  2. Division of Oncological Urology, Department of Urology, University of Köln, Köln, Germany

    Axel Heidenreich

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Necchi, A., Raggi, D., Giannatempo, P. (2018). Role of Neoadjuvant and Adjuvant Chemotherapy in Penile Cancer. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_37-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_37-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation